Interleukin-6, its role in fibrosing conditions

Cytokine and Growth Factor Reviews

Volumn 23, Issue 3, 2012, Pages 99-107

  O'Reilly, Steven ^a   Ciechomska, Marzena ^a   Cant, Rachel ^a   Hügle, Thomas ^a   van Laar, Jacob M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Fibrosis; Interleukin 6; Interleukin 6 signalling; Systemic sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA;

APOPTOSIS; CELL KINETICS; DOWN REGULATION; FIBROSIS; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INTERLEUKIN 6 GENE; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SHORT SURVEY; SIGNAL TRANSDUCER OF ACTIVATION AND TRANSDUCTION 1 GENE; SYSTEMIC SCLEROSIS;

ACTINS; ANIMALS; CYTOKINE RECEPTOR GP130; FIBROSIS; HUMANS; INTERLEUKIN-6; MICE; MOLECULAR TARGETED THERAPY; RECEPTORS, INTERLEUKIN-6; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84861712626     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.04.003     Document Type: Short Survey

References (84)

1. Ishihara K., Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine and Growth Factor Reviews 2002, 13:357-368.
2. Nishimoto N., Sasai M., Shima Y. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000, 95:56-61.
3. Alonzi T., Fattori E., Lazzaro D. Interleukin 6 is required for the development of collagen-induced arthritis. Journal of Experimental Medicine 1998, 187:461-468.
4. Samoilova E.B., Horton J.L., Hilliard B., Liu T.-S.T., Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. Journal of Immunology 1998, 161:6480-6486.
5. Hirano T., Matsuda T., Turner M. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. European Journal of Immunology 1988, 18:1797-1802.
6. Lin Z.-Q., Kondo T., Ishida Y., Takayasu T., Mukaida N. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. Journal of Leukocyte Biology 2003, 73:713-721.
7. Gallucci R.M., Simeonova P.P., Matheson J.M. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. The FASEB Journal 2000, 14:2525-2531.
8. Muraguchi A., Kishimoto T., Miki Y. T cell-replacing factor-(TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. Journal of Immunology 1981, 127:412-416.
9. Teranishi T., Hirano T., Arima N., Onoue K. Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor-(TRF) like factor(s). Journal of Immunology 1982, 128:1903-1908.
10. Hirano T., Yasukawa K., Harada H. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
11. Haegeman G., Content J., Volckaert G., Derynck R., Tavernier J., Fiers W. Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. European Journal of Biochemistry 1986, 159:625-632.
12. Saito M., Yoshida K., Hibi M., Taga T., Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. Journal of Immunology 1992, 148:4066-4071.
13. Yoshida K., Taga T., Saito M. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:407-411.
14. Jenkins B.J., Roberts A.W., Najdovska M., Grail D., Ernst M. The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood 2005, 105:3512-3520.
15. Derouet D., Rousseau F., Alfonsi F. Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:4827-4832.
16. Kopf M., Baumann H., Freer G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
17. Masu Y., Wolf E., Holtmann B., Sendtner M., Brem G., Thoenen H. Disruption of the CNTF gene results in motor neuron degeneration. Nature 1993, 365:27-32.
18. Stewart C.L., Kaspar P., Brunet L.J. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 1992, 359:76-79.
19. Escary J.-L., Perreau J., Dumenil D., Ezine S., Brulet P. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 1993, 363:361-364.
20. Betz U.A.K., Bloch W., van den Broek M. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. Journal of Experimental Medicine 1998, 188:1955-1965.
21. Stahl N., Boulton T., Farruggella T. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994, 263:92-95.
22. Matthews V., Schuster B., Schütze S. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). Journal of Biological Chemistry 2003, 278:38829-38839.
23. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 2011, 121:3375-3383.
24. Vermes C., Jacobs J.J., Zhang J., Firneisz G., Roebuck K.A., Glant T.T. Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts. Journal of Biological Chemistry 2002, 277:16879-16887.
25. Mülberg J., Schooltink H., Stoyan T. The soluble interleukin-6 receptor is generated by shedding. European Journal of Immunology 1993, 23:473-480.
26. Horiuchi S., Koyanagiu Y., Zhouu Y. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. European Journal of Immunology 1994, 24:1945-1948.
27. Garbers C., Jänner N., Chalaris A. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. Journal of Biological Chemistry 2011, 286:14804-14811.
28. Jones S.A., Novick D., Horiuchi S., Yamamoto N., Szalai A.J., Fuller G.M. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. Journal of Experimental Medicine 1999, 189:599-604.
29. Chalaris A., Rabe B., Paliga K. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007, 110:1748-1755.
30. Kahaleh B. The microvascular endothelium in scleroderma. Rheumatology (Oxford) 2008, 47:v14-v15.
31. Jostock T., Müllberg J., Özbek S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. European Journal of Biochemistry 2001, 268:160-167.
32. McLoughlin R.M., Hurst S.M., Nowell M.A. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. Journal of Immunology 2004, 172:5676-5683.
33. Nowell M.A., Williams A.S., Carty S.A. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. Journal of Immunology 2009, 182:613-622.
34. Naka T., Narazaki M., Hirata M. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387:924-929.
35. Croker B.A., Krebs D.L., Zhang J.-G. SOCS3 negatively regulates IL-6 signaling in vivo. Nature Immunology 2003, 4:540-545.
36. Lang R., Pauleau A.-L., Parganas E. SOCS3 regulates the plasticity of gp130 signaling. Nature Immunology 2003, 4:546-550.
37. Croker B.A., Kiu H., Pellegrini M. IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunology and Cell Biology 2012, 90:124-129.
38. Ogata H., Chinen T., Yoshida T. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-[beta]1 production. Oncogene 2006, 25:2520-2530.
39. Liu Q., Liu S., Shi Y. Suppressors of cytokine signaling inhibit tubular epithelial cell-myofibroblast transdifferentiation. American Journal of Nephrology 2011, 34:142-151.
40. Ghazizadeh M., Tosa M., Shimizu H., Hyakusoku H., Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. Journal of Investigative Dermatology 2006, 127:98-105.
41. Ramsay A., Husband A., Ramshaw I. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994, 264:561-563.
42. Baker P.J., Dixon M., Evans R.T., Dufour L., Johnson E., Roopenian D.C. CD4+ T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infection and Immunity 1999, 67:2804-2809.
43. Cressman D.E., Greenbaum L.E., DeAngelis R.A. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274:1379-1383.
44. Natsume M., Tsuji H., Harada A. Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride-treated IL-6-deficient mice. Journal of Leukocyte Biology 1999, 66:601-608.
45. Peters M., Blinn G., Jostock T. Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 2000, 119:1663-1671.
46. Wang X.-P., Schunck M., Kallen K.-J. The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. Journal of Investigative Dermatology 2003, 123:124-131.
47. Martin P. Wound healing-aiming for perfect skin regeneration. Science 1997, 276:75-81.
48. Gallucci R.M., Lee E.G., Tomasek J.J. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. Journal of Investigative Dermatology 2006, 126:561-568.
49. Needleman B.W., Wigley F.M., Stair R.W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis and Rheumatism 1992, 35:67-72.
50. Hasegawa M., Sato S., Ihn H., Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 1999, 38:612-617.
51. Yoshizaki A., Yanaba K., Ogawa A., Asano Y., Kadono T., Sato S. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis and Rheumatism 2011, 63:3575-3585.
52. Briso E.M., Dienz O., Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. Journal of Immunology 2008, 180:7102-7106.
53. Jones G.W., McLoughlin R.M., Hammond V.J. Loss of CD4+ T Cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. Journal of Immunology 2010, 184:2130-2139.
54. Kawaguchi Y., Hara M., Wright T.M. Endogenous IL-1 alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. Journal of Clinical Investigation 1999, 103:1253-1260.
55. Silacci P., Dayer J.-M., Desgeorges A., Peter R., Manueddu C., Guerne P.-A. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. Journal of Biological Chemistry 1998, 273:13625-13629.
56. Wang J.C. Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia. Leukemia and Lymphoma 2005, 46:1261-1268.
57. Simon F., Bergeron D., Larochelle S. Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns 2012, 38:421-427.
58. Ramos C., Montaño M., Garci{dotless}óa-Alvarez J. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. American Journal of Respiratory Cell and Molecular Biology 2001, 24:591-598.
59. Selman M., Ruiz V., Cabrera S. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?. American Journal of Physics 2000, 279:L562-L574.
60. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. Journal of Cell Science 2002, 115:3719-3727.
61. Sohara N., Trojanowska M., Reuben A. Oncostatin M stimulates tissue inhibitor of metalloproteinase-1 via a MEK-sensitive mechanism in human myofibroblasts. Journal of Hepatology 2002, 36:191-199.
62. Shingu M., Nagai Y., Isayama T., Naono T., Nobunaga M. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clinical and Experimental Immunology 1993, 94:145-149.
63. Guo S.-Y., Shen X., Yang J. TIMP-1 mediates the inhibitory effect of interleukin-6 on the proliferation of a hepatocarcinoma cell line in a STAT3-dependent manner. Brazilian Journal of Medical and Biological Research 2007, 40:621-631.
64. Smart D.E., Vincent K.J., Arthur M.J.P. JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. Journal of Biological Chemistry 2001, 276:24414-24421.
65. Smart D.E., Green K., Oakley F. JunD is a profibrogenic transcription factor regulated by Jun N-terminal kinase-independent phosphorylation. Hepatology 2006, 44:1432-1440.
66. Cavet J., Dickinson A.M., Norden J., Taylor P.R.A., Jackson G.H., Middleton P.G. Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001, 98:1594-1600.
67. Chen X., Das R., Komorowski R. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009, 114:891-900.
68. Noguchi D., Wakita D., Ohkuri T. Blockade of IL-6-signaling inhibits the pathogenesis of CD4+ T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen. Immunology Letters 2011, 136:146-155.
69. Tawara I., Koyama M., Liu C. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clinical Cancer Research 2011, 17:77-88.
70. Drobyski W.R., Pasquini M., Kovatovic K. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biology of Blood and Marrow Transplantation 2011, 17:1862-1868.
71. Zhang W., Wang W., Yu H. Interleukin 6 underlies angiotensin II-Induced hypertension and chronic renal damage. Hypertension 2012, 59:136-144.
72. Chen X., Wang J., Zhou F., Wang X., Feng Z. STAT proteins mediate angiotensin II-induced production of TIMP-1 in human proximal tubular epithelial cells. Kidney International 2003, 64:459-467.
73. Pang M., Ma L., Gong R. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney International 2010, 78:257-268.
74. Lim C.P., Phan T.T., Lim I.J., Cao X. Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. Journal of Investigative Dermatology 2008, 129:851-861.
75. Meléndez G.C., McLarty J.L., Levick S.P., Du Y., Janicki J.S., Brower G.L. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010, 56:225-231.
76. Mir S.A., Chatterjee A., Mitra A., Pathak K., Mahata S.K., Sarkar S. Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. Journal of Biological Chemistry 2012, 287:2666-2677.
77. Park C.S., Chung S.W., Ki S.Y. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. American Journal of Respiratory and Critical Care Medicine 2000, 162:1162-1168.
78. Pedroza M., Schneider D.J., Karmouty-Quintana H. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS ONE 2011, 6:e22667.
79. McFarland-Mancini M.M., Funk H.M., Paluch A.M. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. Journal of Immunology 2010, 184:7219-7228.
80. Terao M., Murota H., Kitaba S., Katayama I. Tumor necrosis factor-α processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Experimental Dermatology 2010, 19:38-43.
81. Shima Y., Kuwahara Y., Murota H. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010, 49:2408-2412.
82. Kitaba S., Murota H., Terao M. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. American Journal of Pathology 2012, 180:165-176.
83. Lotz M., Guerne P.A. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). Journal of Biological Chemistry 1991, 266:2017-2020.
84. Sano S., Itami S., Takeda K. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO Journal 1999, 18:4657-4668.